SpotitEarly is developing an at-home breath test utilising trained dogs and AI for the early detection of common cancers. The test analyses volatile organic compounds (VOCs) in breath samples, which can indicate the presence of cancer. The company's LUCID platform integrates proprietary hardware and software to analyse data points, verifying canine detection signals.
The test involves breathing into a mask for sample collection, with analysis performed in a lab. Clinical trials have demonstrated high accuracy in early-stage cancer detection. SpotitEarly plans to launch US clinical trials for breast and lung cancer, seeking FDA clearance. The at-home multi-cancer breath test kit is expected to be available to consumers in 2026.
Subscribe for Weekly Updates
Stay ahead with our weekly AI and tech briefings, delivered every Tuesday.
